Ai-enhanced imaging platform for herbicide screening
Quantiscope PBC offers an AI-powered platform for rapid herbicide screening using high-throughput image analysis. This solution accelerates herbicide development by quantifying efficacy and safety through automated image analysis, leveraging AI/ML models for cell detection and phenotyping.
Overview
Quantiscope PBC presents an advanced AI-enhanced imaging platform designed to accelerate herbicide development. By applying machine learning (ML) to analyze high-content brightfield images, this platform automates the screening of biological assays, quantifying both the efficacy and safety of potential herbicides. The innovation lies in its ability to process and analyze large volumes of data rapidly, identifying top herbicide candidates without prior knowledge of experimental details. This technology promises to significantly enhance the efficiency of phenotypic discovery methods in agriculture.
Technical specifications
- Automated Cell Detection and Segmentation: Utilizes AI/ML tools to autonomously identify and segment plant cells in high-content images, similar to face detection technology.
- Phenotypic Signature Analysis: Transforms cellular morphology and structure into quantitative data, enabling the recognition of cellular functions from image data.
- High-throughput Screening: Capable of analyzing millions of cells across thousands of images, providing a robust, rapid screening process for herbicide treatments.
Technology readiness level
The platform has achieved a Technology Readiness Level (TRL) of 6, indicating that it has been tested in relevant environments and is approaching commercialization. Further optimization and validation are planned to enhance its capabilities for high-throughput screening applications.
About Quantiscope PBC
Quantiscope PBC develops an AI-powered enterprise platform called phenotypIQ that automates biological quantification to support preclinical drug discovery and research. By applying machine learning and computer vision to microscopic images, the platform converts high-content biological imaging into actionable phenotypic data. This technology mirrors facial recognition methods, analyzing approximately 1,500 nodes of a cell to model cellular responses to various treatments, including small molecules, biologics, and genetic therapies. The cloud-based, plug-and-play solution is designed to integrate seamlessly into existing therapeutic pipelines, enabling researchers to conduct automated hit identification, enhance optimization, and improve decision-making regarding efficacy and toxicity.
The platform aims to streamline the drug development process, offering significant value to researchers by simplifying data interpretation and reducing the time required for clinical candidate selection. By democratizing access to advanced phenotypic modeling, Quantiscope supports diverse applications ranging from rare disease research to pandemic responsiveness and biodefense. Founded in 2022 and incubated at Altitude Lab, the company has engaged in pilot studies with various biotech and pharmaceutical partners, utilizing its SaaS-based tools to de-risk development and drive innovations in life sciences and biomanufacturing.
Inquire about this partnering listing
Industry applications
delivered to your inbox.